196 related articles for article (PubMed ID: 22067315)
1. Type 2 corticotropin-releasing factor receptor in the ventromedial nucleus of hypothalamus is critical in regulating feeding and lipid metabolism in white adipose tissue.
Chao H; Digruccio M; Chen P; Li C
Endocrinology; 2012 Jan; 153(1):166-76. PubMed ID: 22067315
[TBL] [Abstract][Full Text] [Related]
2. Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis.
Chen P; Vaughan J; Donaldson C; Vale W; Li C
Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E337-45. PubMed ID: 19952342
[TBL] [Abstract][Full Text] [Related]
3. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic expression of urocortin 3 and the type 2 corticotropin-releasing factor receptor is regulated according to feeding state in lean but not obese Zucker rats.
Poulin AM; Lenglos C; Mitra A; Timofeeva E
Neuropharmacology; 2012 Jul; 63(1):147-53. PubMed ID: 22227020
[TBL] [Abstract][Full Text] [Related]
5. Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet.
Jamieson PM; Cleasby ME; Kuperman Y; Morton NM; Kelly PA; Brownstein DG; Mustard KJ; Vaughan JM; Carter RN; Hahn CN; Hardie DG; Seckl JR; Chen A; Vale WW
Diabetologia; 2011 Sep; 54(9):2392-403. PubMed ID: 21667214
[TBL] [Abstract][Full Text] [Related]
6. Urocortin in the ventromedial hypothalamic nucleus acts as an inhibitor of feeding behavior in rats.
Ohata H; Suzuki K; Oki Y; Shibasaki T
Brain Res; 2000 Apr; 861(1):1-7. PubMed ID: 10751559
[TBL] [Abstract][Full Text] [Related]
7. Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice.
Bradbury MJ; McBurnie MI; Denton DA; Lee KF; Vale WW
Endocrinology; 2000 Aug; 141(8):2715-24. PubMed ID: 10919255
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold.
Bale TL; Anderson KR; Roberts AJ; Lee KF; Nagy TR; Vale WW
Endocrinology; 2003 Jun; 144(6):2580-7. PubMed ID: 12746321
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-releasing factor overexpression in mice abrogates sex differences in body weight, visceral fat, and food intake response to a fast and alters levels of feeding regulatory hormones.
Wang L; Goebel-Stengel M; Yuan PQ; Stengel A; Taché Y
Biol Sex Differ; 2017; 8():2. PubMed ID: 28101317
[TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing factor receptor type 1, but not type 2, in the ventromedial hypothalamus modulates dopamine release in female rats.
Muramatsu T; Inoue K; Iwasaki S; Yamauchi T; Hayashi T; Kiriike N
Pharmacol Biochem Behav; 2006 Oct; 85(2):435-40. PubMed ID: 17109941
[TBL] [Abstract][Full Text] [Related]
11. Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia-induced hormonal counterregulation.
McCrimmon RJ; Song Z; Cheng H; McNay EC; Weikart-Yeckel C; Fan X; Routh VH; Sherwin RS
J Clin Invest; 2006 Jun; 116(6):1723-30. PubMed ID: 16741581
[TBL] [Abstract][Full Text] [Related]
12. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids.
Chen A; Blount A; Vaughan J; Brar B; Vale W
Endocrinology; 2004 May; 145(5):2445-57. PubMed ID: 14736736
[TBL] [Abstract][Full Text] [Related]
13. Decreased type 2 corticotropin-releasing hormone receptor mRNA expression in the ventromedial hypothalamus during repeated immobilization stress.
Makino S; Asaba K; Nishiyama M; Hashimoto K
Neuroendocrinology; 1999 Sep; 70(3):160-7. PubMed ID: 10516478
[TBL] [Abstract][Full Text] [Related]
14. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.
Fekete EM; Inoue K; Zhao Y; Rivier JE; Vale WW; Szücs A; Koob GF; Zorrilla EP
Neuropsychopharmacology; 2007 May; 32(5):1052-68. PubMed ID: 17019404
[TBL] [Abstract][Full Text] [Related]
15. Effects of gold thioglucose treatment on central corticotrophin-releasing hormone systems in mice.
Noguchi T; Makino S; Shinahara M; Nishiyama M; Hashimoto K; Terada Y
J Neuroendocrinol; 2013 Apr; 25(4):340-9. PubMed ID: 23253150
[TBL] [Abstract][Full Text] [Related]
16. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis.
Li C; Chen P; Vaughan J; Lee KF; Vale W
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4206-11. PubMed ID: 17360501
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of type 2 CRH receptor mRNA in the VMH by glucocorticoids and starvation.
Makino S; Nishiyama M; Asaba K; Gold PW; Hashimoto K
Am J Physiol; 1998 Oct; 275(4):R1138-45. PubMed ID: 9756544
[TBL] [Abstract][Full Text] [Related]
18. Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.
Tezval H; Jurk S; Atschekzei F; Becker JU; Jahn O; Serth J; Kuczyk MA
World J Urol; 2009 Dec; 27(6):825-30. PubMed ID: 19437022
[TBL] [Abstract][Full Text] [Related]
19. Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells.
Chao H; Li H; Grande R; Lira V; Yan Z; Harris TE; Li C
Mol Endocrinol; 2015 Jun; 29(6):831-41. PubMed ID: 25875045
[TBL] [Abstract][Full Text] [Related]
20. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart.
Brar BK; Jonassen AK; Egorina EM; Chen A; Negro A; Perrin MH; Mjøs OD; Latchman DS; Lee KF; Vale W
Endocrinology; 2004 Jan; 145(1):24-35; discussion 21-3. PubMed ID: 12970163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
